Dr. Mohamed Aseafan

Consultant Medical Oncologist; Head, Oncology Division

Dr. Mohamed Aseafan is a highly regarded Saudi medical oncologist based in Riyadh. He currently serves as the Head of Oncology and Consultant Medical Oncologist at the Security Forces Hospital (SFH) and is recognized for his active regional involvement in genitourinary (GU), gastrointestinal (GI), and gynecologic malignancies.

Current Roles & Positions
• Head of Oncology: Directs clinical oncology services at the Security Forces Hospital (SFH) Program in Riyadh.
• Academic Appointment: Serves as a Clinical Assistant Professor of Medicine at Princess Nourah bint Abdulrahman University (PNU).
• Regional Board Panels: Serves as an expert moderator and panelist for major scientific summits, including the International Genitourinary Cancers Conference (IGCC).
• Scientific Committee Leadership: Appointed to regional leadership bodies, including the scientific committee for the Middle East and Mediterranean Association of Gynecologic Oncologists (MEMAGO).

Clinical Specialization
Dr. Aseafan's clinical focus spans several key sub-specialties within solid tumor medical oncology:
• Genitourinary (GU) Cancers: Expert in the systemic management (immunotherapy, targeted therapies, and chemotherapy) of advanced prostate, bladder, renal (kidney), and testicular cancers.
• Gastrointestinal (GI) Cancers: Highly involved in treating aggressive GI tracts, including advanced biliary tract cancers, gastric/gastroesophageal junction tumors, and small bowel adenocarcinomas.
• Gynecologic Oncology: Contributes to local and regional standard-of-care updates for women's reproductive system cancers.
Research Contributions

Dr. Aseafan is a productive clinician-researcher with numerous peer-reviewed contributions tracking cancer clinical outcomes across Saudi Arabia:Biliary & Gastric Cancer Trials: Co-investigator on specialized clinical studies, such as Phase II trials evaluating modified chemotherapy regimens (like FOLFIRINOX) for advanced biliary tract malignancies.
Prognostic Mapping: Published institutional experiences evaluating real-world survival outcomes and prognostic factors for metastatic stomach and small bowel adenocarcinomas in Saudi patients.